Clinical Trial Update: Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of non-myeloablative HLA-mismatched ex-vivo T-cell depleted stem cell transplantation for hematologic malignancies was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lymphoma, Leukemia | Phase 2 | Status: TERMINATED